As the Fed was meeting to consider cutting interest rates, it lost control of the very benchmark rate that it manages.Market Insiderread more
Activists with Black Lives Matter, who met privately with Buttigieg in the weeks after police shot and killed Eric Logan, say the 37-year-old mayor brushed off their concerns...2020 Electionsread more
Wall Street economists think the Fed will cut rates by 25 basis points at its September meeting but have differing views about what will happen in the future.Marketsread more
Trump said he "is revoking" a federal waiver that allowed the state to craft its own rules on greenhouse gas emissions from vehicles.Politicsread more
FedEx CEO Fred Smith mentioned Amazon as one of his competitors during Tuesday's earnings call, a shift in stance for a company that's long downplayed Amazon's move into the...Technologyread more
J.P. Morgan Chase chief Dimon says he doesn't think the U.S. is close to recession and called the Fed's Powell "a quality human."Marketsread more
Check out the companies making headlines in midday trading.Market Insiderread more
Drone and missile debris recovered by investigators at the Saudi Aramco attack site is proof of Iranian culpability, a Saudi defense ministry representative told media on...World Politicsread more
FedEx CEO Fred Smith is "basically implying that we're going to import" a global slowdown, says CNBC's Jim Cramer.Investingread more
Fans of "The Princess Bride" are screaming "inconceivable!" after the CEO of Sony Pictures Entertainment said pitches had been made by "very famous people" to remake the...Entertainmentread more
With the major pharmaceutical companies done with fourth-quarter earnings, J.P. Morgan is letting clients know which companies look the best down the road.
The group as a whole performed well thanks to strong fundamentals with earnings mostly above expectations, according to analyst Chris Schott.
"Most companies in our coverage reported solid core product trends and in-line/better-than-expected earnings per share, augmented by a greater-than-expected tax benefit," Schott wrote to clients on Wednesday. "Looking forward, with the Major Pharma group still trading at a steep discount to the S&P 500, we see a number of opportunities in the sector."
Schott highlighted the four names J.P. Morgan finds most attractive after the latest earnings season, complete with updates on company performance.
Here are some of the pharma stocks J.P. Morgan has rated overweight.